A Roadmap to Precision Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
Year: 2025
Type: article
Abstract: Immunotherapy has revolutionized the treatment of early-stage non-small cell lung cancer; yet many patients fail to achieve long-lasting benefit, partially because of incomplete or inconsistent biomarker predictions. Integrative multiomics, combining tumor-intrinsic, immune microenvironment, and systemic factors, offer a more comprehensive framework for precision immunotherapy, enabling improved patient stratification, treatment selection and outcomes.
Source: Cancer Discovery
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Targeting Lung Cancer Vulnerabilities, G731872730, Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy, Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer, Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer
OpenAlex ID: W4407914684